GT Biopharma, Inc., a clinical-stage immuno-oncology company, is committed to developing innovative therapies using its proprietary TriKE® NK cell technology. The firm recently announced it filed an IND application with the US FDA for its new drug, GTB-3650.

The market is expected to benefit from constant growth in the genomics and genetic modification markets as progress in genetic instruments simplifies oligonucleotide synthesis.

Everest Medicines, a biopharma company, announced that China's National Medical Products Administration has accepted their IND application for the drug candidate zetomipzomib in China.

Neuraminidase inhibitors are drugs that target the neuraminidase enzyme, crucial for combating influenza virus infections.

FDA Grants Approval for CARsgen's Experimental Treatment CT071 for Use in Cases of Recurrent Multiple Myeloma and Primary Plasma Cell Leukemia After Prior Therapies Fail.

Compounds resembling key metabolites can compete with them or disrupt their use, or get incorporated into biological macromolecules, creating faulty structures that hinder cell growth and can be lethal.

Brenig Therapeutics Reveals Enhanced Safety Metrics for its LRRK2 Blocker BT-0267 Featuring Notable CSF-to-Blood Concentration at the Parkinson's Disease Symposium.

Mcl-1 inhibitors are drugs that target the Mcl-1 protein, crucial for regulating cell survival and apoptosis.

The prominent science and technology corporation, Merck, has declared a formal licensing contract with the Shanghai-based firm Abbisko Therapeutics Co. Ltd.

In biology, a sense strand or coding strand is the part of the double-stranded DNA that carries the translatable code, running in the 5' to 3' direction.

Ascletis Pharma Inc. has declared the commencement of a pivotal Phase III clinical study for its fatty acid synthase inhibitor, ASC40 (Denifanstat) , aimed at addressing the therapeutic needs of individuals with moderate to severe acne vulgaris.

NS5A inhibitors: Revolutionizing hepatitis C treatment with high efficacy and future potential.